What Schedule T Requires from Medicine Manufacturers?
Schedule T sits within the Drugs Rules, 1945. It establishes GMP controls for relevant traditional medicines.
Medicines and Manufacturing Activities Covered
It covers Ayurvedic, Siddha and Unani medicines, including classical and proprietary formulations. Sowa-Rigpa appears in various updated regulatory provisions.
Manufacturers must check product classifications and licence conditions rather than assume universal coverage.
Homoeopathic medicines follow Schedule M-I, not Schedule T. Schedule TA separately addresses records of raw materials used by relevant manufacturers and associated reporting.
Schedule T concerns how manufacturers prepare and control medicines. Product authorisation, permitted ingredients, safety evidence and labelling involve additional provisions.
GMP Compliance Versus Manufacturing Permission
A manufacturing licence authorises specified activities under the applicable rules. GMP requirements govern the physical facilities and quality practices supporting those activities.
A GMP certificate evidences compliance but does not automatically approve additional formulations.
A limited exemption applies to qualifying registered practitioners preparing medicines for their own patients without selling those medicines commercially.
Ordinary market manufacturing cannot claim that exemption.
West Bengal Requirements and the 2026 Amendments
The state licensing authority administers relevant manufacturing authorisations and inspections. Central drug regulations establish the GMP framework that local applicants must address.
What Changed in July 2026?
The Drugs (Eleventh Amendment) Rules, 2026 revised Schedule T, strengthening provisions concerning premises, raw material controls, batch records, quality assurance and internal audits.
The notification provides until 31 July 2029 for compliance with amendments introduced into Schedule T. However, existing applicable GMP obligations continue during that period.
Manufacturers should distinguish existing requirements from changes covered by the transition period.
The amendment also introduced product coding and other provisions outside Schedule T. Those distinct obligations require separate review rather than automatic classification as GMP rules.
Local Licensing and Facility Changes
An applicant seeking an ayush license in West Bengal should first identify the relevant medicine system, dosage forms and manufacturing arrangement.
Applicants should verify the current submission channel, documents and single-window arrangements with the state authority.
Existing manufacturers should reassess compliance when adding production lines, changing equipment, extending premises or introducing formulations with different processing risks.
Manufacturing Premises and Infrastructure Standards
Schedule T connects building design with prevention of contamination and production errors. A clean appearance alone cannot establish suitability for pharmaceutical operations.
Layout, Surfaces and Material Movement
Facilities should provide distinct functional arrangements for material receipt, storage, manufacture, packaging, quality control and finished goods where the applicable requirements demand them.
Work areas need adequate space for equipment, personnel and orderly movement. Dust-producing operations require appropriate controls against cross-contamination.
Cleanable surfaces, drainage and pest prevention limit contamination. Premises maintenance must not compromise ongoing production.
Manufacturers should separate incompatible activities and restrict sensitive-area access. Logical material movement reduces confusion between incoming ingredients and approved batches.
Water, Environmental Controls and Waste
Water used in manufacturing must meet the applicable quality requirements. Manufacturers should document relevant treatment arrangements and monitor suitability for intended processes.
Ventilation, lighting, temperature and humidity must support the products and equipment concerned. Particular materials may require additional environmental controls.
Waste handling should account for industrial effluents, hazardous substances and relevant Schedule E(I) ingredients. Other environmental obligations may apply independently.
In addition, operators must consider safe container washing, drying and storage so that packaging does not introduce new contaminants.
Plant, Machinery and Dosage-Specific Requirements
Manufacturers should select machinery according to approved formulations, production capacity and processing methods. Schedule T does not require identical equipment across all dosage forms.
Equipment for Common Preparations
Powders: Grinders, sieves and mixers require suitable dust control, cleaning and product segregation.
Tablets and pills: Granulation, compression or shaping equipment must suit the approved manufacturing process.
Medicated oils: Heating, mixing and filtration arrangements should accommodate the ingredients and processing temperatures.
Decoctions: Boiling vessels, filtration equipment and transfer systems must support controlled extraction and handling.
Extracts: Concentration, drying and other processing equipment depend on the approved formulation and plant configuration.
Schedule T Part II lists category-specific machinery and premises requirements. Operators should verify the relevant entries before selecting a building.
Maintenance, Cleaning and Calibration
Equipment should permit thorough cleaning and safe operation. Written procedures should cover usage, cleaning, servicing and calibration where applicable.
A mixer carrying residue from an earlier batch creates a cross-contamination risk. Similarly, inaccurate weighing equipment can undermine formulation consistency.
Operators should document checks and faults, remove unsuitable equipment from service and verify satisfactory performance before returning it to production.
Qualified Personnel and Manufacturing Hygiene
Competent technical supervision supports compliance with authorised formulations and manufacturing procedures. The Drugs Rules prescribe qualifications according to relevant manufacturing activities.
Production and Quality Responsibilities
Manufacturers must appoint suitable technical personnel under applicable licensing provisions. They should verify qualifications and employment arrangements against current rules.
Production supervisors oversee processing and batch documentation. Quality personnel examine specifications, testing outcomes and product release requirements.
Separating quality decisions from production pressures strengthens accountability, particularly when unexpected analytical results or process deviations arise.
Training and Worker Health
Workers need instruction appropriate to their duties, including personal hygiene, protective clothing, cleaning procedures and safe material handling.
Training should cover actual equipment and processes rather than rely on general induction alone. Relevant records should demonstrate the instruction provided.
Personnel health arrangements and restrictions concerning infectious illness help reduce contamination risks. Special processes involving hazardous ingredients require further precautions.
Raw Material Identification, Storage and Traceability
Traditional medicines may contain botanicals, minerals, metals or animal-derived ingredients. Their different characteristics demand appropriate receipt, identification and storage controls.
Receipt and Quality Assessment
Manufacturers should verify supplier, identity, packaging and purchasing records upon receipt.
Raw materials need clear identification and suitable quarantine arrangements until authorised quality review permits their use. Separate lots require traceable identification.
Botanical materials warrant attention to species, plant part, moisture, pests and other contaminants. Applicable pharmacopoeial specifications determine relevant quality characteristics.
Materials with strong odours, hazardous properties or special storage needs may require segregated conditions. Their controls should reflect actual risks.
Preventing Material Mix-Ups
Storage arrangements should distinguish materials under test, approved ingredients and rejected consignments. Inventory records should connect every issue to the correct batch.
Stock rotation reduces the chance of using expired materials. Nevertheless, a first-in-first-out approach never overrides a relevant expiry or retesting requirement.
Manufacturers should investigate discrepancies between quantities received, dispensed and consumed. Such reconciliation can expose recording mistakes or material losses.
Production Procedures and Batch Manufacturing Records
Written production instructions allow trained staff to repeat a process consistently. Schedule T requires documentation that supports verification and inspection.
Essential Operating Procedures
Manufacturers should establish relevant standard operating procedures covering:
Receipt and sampling: Identify materials and prevent contamination during examination.
Weighing and dispensing: Verify quantities and trace the approved raw material lots.
Manufacturing: Define processing stages, controls and authorised personnel.
Cleaning: Specify methods, responsibilities and checks before subsequent batches.
Packaging: Verify correct labels, containers and approved product identities.
Deviations: Record unexpected events and investigate their potential quality impact.
Procedures should reflect actual equipment and activities. Staff cannot reliably follow instructions that describe obsolete production arrangements.
What a Batch Record Should Establish
A batch manufacturing record connects ingredients, operators, equipment and processing stages to one identifiable production lot.
It should capture quantities, analytical references, observations, yields and signatures.
Where traditional techniques such as Bhavana or Puta apply, records should describe the relevant processing steps and associated checks.
Before batch release, responsible quality personnel should review manufacturing documentation alongside testing results. Missing records may prevent adequate verification of the batch.
Quality Control and Testing Arrangements
Quality control assesses materials and finished medicines against relevant specifications. Schedule T permits certain approved external laboratory arrangements within its applicable provisions.
Laboratory Responsibilities
Manufacturers must ensure suitable testing arrangements for identification and applicable quality characteristics. Relevant pharmacopoeial methods and product specifications inform the testing programme.
Testing may address identity, purity, physicochemical properties or microbiological quality, depending on the material and medicine concerned.
Outsourcing permitted tests does not transfer the manufacturer’s overall accountability for material decisions, reliable records and compliant product release.
Where a unit operates an internal laboratory, it should assess qualified staff, suitable space, appropriate instruments and maintenance requirements.
Handling Unsatisfactory Results
Quality personnel should investigate failing results before release. Retesting must not serve merely to disregard inconvenient findings.
Appropriate records connect test methods, observations, samples and decisions. Control samples and stability documentation also support later quality investigations.
Retained reference samples can also support investigations into subsequent product complaints.
For proprietary formulations, manufacturers should maintain the specifications required for the approved product and applicable rules.
Packaging, Labelling and Finished Product Storage
Packaging controls protect identity and prevent mix-ups after production. Manufacturers should inspect containers and verify printed information before use.
Release and Distribution Controls
Labels must satisfy relevant labelling rules as well as manufacturing controls. Requirements for batch details, product identification and other declarations arise under applicable provisions.
Finished products should remain segregated pending quality review. Only authorised batches should enter distribution, with appropriate storage conditions.
Distribution records should identify affected batches and their destinations. Consequently, a manufacturer can organise targeted action when complaints or recalls arise.
Licensing, Inspections and Continuing Compliance
West Bengal applicants should prepare manufacturing facilities and quality systems before seeking the applicable authorisation. Inspectors may examine premises, records and working practices.
Preparation for Application and Inspection
A practical sequence involves selecting the correct licence category, preparing appropriate premises, appointing technical staff and organising quality testing arrangements.
Applicants should assemble relevant layout plans, personnel details, product particulars and supporting documents under the prescribed procedure.
During inspection preparation, managers should compare written procedures with actual operations. Inspectors may examine storage status, equipment logs, batch records and sanitation.
Where authorities identify deficiencies, manufacturers should document corrective measures and confirm their effectiveness instead of merely providing written assurances.
Continuing Duties and Compliance Failures
Compliance requires regular review of procedures, equipment, suppliers and personnel training. Internal audits can identify gaps before they affect medicine quality.
Common problems include incomplete batch records, damaged storage containers, outdated cleaning instructions and undocumented quality decisions.
Manufacturers should assess complaints, investigate quality defects and maintain appropriate adverse reaction reporting arrangements under the applicable provisions.
Significant deficiencies may lead to regulatory scrutiny or enforcement according to the circumstances and governing law; outcomes cannot be presumed.
Practical Readiness Checklist for Manufacturers
Before commencing or expanding production, operators can review critical operational arrangements against the applicable version of Schedule T.
Confirm medicine categories, formulations and appropriate manufacturing authorisation.
Assess layout, hygiene, water quality and material flow.
Match equipment with production processes and applicable specifications.
Verify technical staffing, hygiene arrangements and documented training.
Establish raw material controls, testing procedures and batch traceability.
Check packaging approval, finished goods release and distribution records.
Schedule internal audits, maintenance and corrective action reviews.
Identify 2026 amendments requiring compliance within the transitional period.
FAQs
1. Does Schedule T apply to every AYUSH medicine manufacturer?
Schedule T principally governs Good Manufacturing Practices for Ayurvedic, Siddha and Unani medicines, with updated provisions also addressing Sowa-Rigpa. Homoeopathic manufacturing follows Schedule M-I.
The precise obligations depend on the medicine system, manufacturing activity and applicable licensing provisions. Manufacturers should verify their product classifications before establishing GMP arrangements.
2. Is a manufacturing licence the same as GMP certification?
No. A manufacturing licence authorises specified regulated activities, while GMP requirements govern production conditions and quality controls.
Certification provides relevant evidence of compliance within its scope.
Manufacturers must also satisfy product-specific approval, testing and labelling requirements where applicable. Holding one authorisation does not automatically satisfy every other obligation.
3. Can a small Ayurvedic manufacturing unit avoid Schedule T requirements?
Small size does not generally exempt commercial Ayurvedic medicine manufacturing from applicable GMP obligations.
The facility should match its layout, machinery and quality arrangements to the proposed dosage forms.
Particular exemptions concern qualifying practitioners preparing medicines for their own patients without commercial sale, rather than ordinary small manufacturing businesses.
4. What records are important during a GMP inspection?
Inspectors may review batch manufacturing records, raw material registers, laboratory reports, equipment cleaning logs, maintenance documents and staff training records.
Complaint investigations, product release decisions and distribution records also matter.
The records should accurately describe operations and enable traceability, rather than merely demonstrate that the manufacturer possesses blank templates.
5. Can AYUSH manufacturers use external laboratories for testing?
Applicable Schedule T provisions recognise certain government-approved external testing arrangements. However, manufacturers remain responsible for ensuring suitable tests, reviewing results and controlling material release.
They should verify the laboratory’s relevant approval and testing scope, maintain supporting reports and provide suitable internal quality oversight for their manufacturing activities.
6. Which infrastructure features support Schedule T compliance?
Manufacturing premises need appropriate working space, sanitation, ventilation, storage and measures against contamination. Water suitability and waste handling also matter.
Specific arrangements depend on products and processes, particularly where operations generate dust or involve hazardous ingredients.
Manufacturers should check relevant Schedule T provisions before designing or modifying a facility.
7. What happens during a regulatory manufacturing inspection?
Inspectors may examine premises, personnel, equipment, records and GMP practices. They can assess whether manufacturing practices reflect approved activities and whether quality controls operate effectively.
Manufacturers should provide accurate records, demonstrate procedures and address identified deficiencies through documented corrective action under the applicable regulatory process.
8. Do the 2026 Schedule T changes apply immediately?
The Drugs (Eleventh Amendment) Rules, 2026 introduced revised Schedule T provisions and a transition period ending on 31 July 2029 for compliance with those amendments.
Existing applicable GMP duties remain relevant meanwhile. Manufacturers should identify changed requirements, assess facility gaps and implement necessary upgrades before the deadline.
9. Can poor raw material storage affect manufacturing approval?
Yes. Unsuitable storage can damage ingredients, increase contamination risks and undermine reliable identification.
Inspectors may examine quarantine practices, segregation, temperature conditions and traceability against applicable requirements.
Manufacturers should control material status, investigate damaged consignments and prevent unapproved ingredients from entering production, particularly where products contain sensitive materials.
10. What should manufacturers do after receiving authorisation?
Manufacturers should maintain controlled processes, equipment servicing, personnel training and appropriate product testing.
They should investigate complaints, preserve relevant records and review changes affecting approved operations.
Regular internal audits help identify corrective actions. Continuing compliance depends on actual manufacturing conduct rather than the initial inspection or licence document alone.
